Evidence map›Paper›PMID 38731860›Full record

ArticleInternational journal of molecular sciences2024

A Multi-Faceted Binding Assessment of Aptamers Targeting the SARS-CoV-2 Spike Protein.

Laia Civit, Nima Moradzadeh, Anna Jonczyk, Patrick Neckermann, Benedikt Asbach, David Peterhoff, Ralf Wagner, Michael Famulok, Günter Mayer, Jørgen Kjems and 1 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Selection and Characterization of SARS-CoV-2 Spike Binding Clickmers.Chembiochem : a European journal of chemical biology · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Laia CivitInterdisciplinary Nanoscience Center, Aarhus University, DK-8000 Aarhus, Denmark.ORCID 0009-0007-0062-8438
Nima MoradzadehLife and Medical Sciences (LIMES), University of Bonn, 53121 Bonn, Germany.ORCID 0009-0002-2484-0621
Anna JonczykLife and Medical Sciences (LIMES), University of Bonn, 53121 Bonn, Germany.ORCID 0009-0005-6047-6785
Patrick NeckermannInstitute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), Regensburg University, 93053 Regensburg, Germany.ORCID 0000-0001-6066-4034
Benedikt AsbachInstitute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), Regensburg University, 93053 Regensburg, Germany.ORCID 0000-0003-1056-8591
David PeterhoffInstitute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), Regensburg University, 93053 Regensburg, Germany.ORCID 0000-0001-5911-6233
Ralf WagnerInstitute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), Regensburg University, 93053 Regensburg, Germany.
Michael FamulokLife and Medical Sciences (LIMES), University of Bonn, 53121 Bonn, Germany.
Günter MayerLife and Medical Sciences (LIMES), University of Bonn, 53121 Bonn, Germany.
Jørgen KjemsInterdisciplinary Nanoscience Center, Aarhus University, DK-8000 Aarhus, Denmark.ORCID 0000-0003-4128-9317
Julián ValeroInterdisciplinary Nanoscience Center, Aarhus University, DK-8000 Aarhus, Denmark.ORCID 0000-0002-5260-2770

Funding

Carlsberg Foundation CF20-0045Carlsberg Foundation CF20-0610Danish National Reseach Foundation DNRF135Deutsche Forschungsgemeinschaft MA3442/7-1European Union H2020-FETOPEN 899619Federal Ministry of Education and Research 01KI20154
6 · The paper itself

Abstract

The COVID-19 pandemic has underscored the critical need for the advancement of diagnostic and therapeutic platforms. These platforms rely on the rapid development of molecular binders that should facilitate surveillance and swift intervention against viral infections. In this study, we have evaluated by three independent research groups the binding characteristics of various published RNA and DNA aptamers targeting the spike protein of the SARS-CoV-2 virus. For this comparative analysis, we have employed different techniques such as biolayer interferometry (BLI), enzyme-linked oligonucleotide assay (ELONA), and flow cytometry. Our data show discrepancies in the reported specificity and affinity among several of the published aptamers and underline the importance of standardized methods, the impact of biophysical techniques, and the controls used for aptamer characterization. We expect our results to contribute to the selection and application of suitable aptamers for the detection of SARS-CoV-2.

Indexed as

Aptamers, NucleotideCOVID-19Protein BindingSARS-CoV-2Spike Glycoprotein, CoronavirusFlow CytometryHumansInterferometryAptamers, NucleotideSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2aptamerscomparative analysisCOVID-19SARS-CoV-2spike protein

Identifiers

PMID38731860
PMCPMC11083479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.